NuvOx Pharma LLC is a Bio-Medical nano-technology company researching advancements to support an innovative platform of oxygen therapeutics to treat life-threatening diseases where hypoxia plays a role. NuvOx's core technology organizes around utilizing one particular perfluorocarbon, dodecafluoropentane (DDFP), which provides multiple advantages for respiratory gas transfer and can be applied to a host of therapeutic indications.The NuvOx Pharma approach is to develop a platform of drugs that - upon intravenous injection - flow through the bloodstream arriving first at the lungs to pick up oxygen and finally to hypoxic tissue where they passively deliver the oxygen. Indications for NuvOx's drug include Stroke (Phase II ready), Oncology (Phase II ready), and Sickle Cell Crisis (Phase Ib ready). Due to their inherent structure, extreme stability and relative lack of inter-molecular attractive forces, perfluorocarbons are known to carry large payloads of gas such as oxygen, carbon dioxide and nitrogen. The main advantage to using DDFP is that it is a liquid at room temperature and ambient pressure, but expands to the gas state at 29 degrees C and ambient pressure. Therefore, upon intravenous injection (at biological temperature (37 degrees C) and standard vascular pressures), a certain amount of expansion occurs in the bloodstream to allow even larger amounts of respiratory gases to be carried.
